Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT.

Larson, Robert E.; Semelka, Richard C.; Bagley, Ann S.; Molina, Paul L.; Brown, Elizabeth D.; Lee, Joseph K. T.

doi:10.1148/radiology.192.2.8029403

Cited by 139 publications

(57 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the arterial phase of contrast enhancement, the arterial contrast material arriving at normal liver is diluted 4:1 by unenhanced blood, but 100% of the flow to the neoplasm contains contrast material (23). Arterial phase images are thus quite useful for detecting hypervascular neoplasms such as hepatocellular carcinoma, focal nodular hyperplasia, hepatic adenomas, and hypervascular metastases (2,4,11,12,16,18). In these early phase images, such lesions will appear bright compared with the largely unenhanced liver parenchyma.…”

Section: Discussionmentioning

confidence: 99%

A multicenter, randomized, double‐blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

Rubin

Desser

Semelka

et al. 1999

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A multicenter, randomized, double‐blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

Rubin

Desser

Semelka

et al. 1999

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

“…The majority of benign, malignant, and inflammatory diseases of the spleen, adrenals, kidneys, pancreas, and organs of the male and female pelvis are well depicted by MRI, and in the hands of experienced practitioners are better elucidated than they would be on CT (72)(73)(74)(75)(76). The superiority of MRI over CT for detecting and characterizing focal liver lesions and liver disease is well established (77)(78)(79)(80). In patients with malignancy, MRI demonstrates an advantage over CT in detecting extrahepatic abdominal disease in many sites (81).…”

Section: Consider Alternatives To Ctmentioning

confidence: 99%

Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI

Semelka

Armao

Elias

et al. 2007

Magnetic Resonance Imaging

195

106

View full text Add to dashboard Cite

“When one admits that nothing is certain one must, I think, also admit that some things are much more nearly certain than others.” Bertrand Russell (1872–1970) Computed tomography (CT) is one of the largest contributors to man‐made radiation doses in medical populations. CT currently accounts for over 60 million examinations in the United States, and its use continues to grow rapidly. The principal concern regarding radiation exposure is that the subject may develop malignancies. For this systematic review we searched journal publications in MEDLINE (1966–2006) using the terms “CT,” “ionizing radiation,” “cancer risks,” “MRI,” and “patient safety.” We also searched major reports issued from governmental U.S. and world health‐related agencies. Many studies have shown that organ doses associated with routine diagnostic CT scans are similar to the low‐dose range of radiation received by atomic‐bomb survivors. The FDA estimates that a CT examination with an effective dose of 10 mSv may be associated with an increased chance of developing fatal cancer for approximately one patient in 2000, whereas the BEIR VII lifetime risk model predicts that with the same low‐dose radiation, approximately one individual in 1000 will develop cancer. There are uncertainties in the current radiation risk estimates, especially at the lower dose levels encountered in CT. To address what should be done to ensure patient safety, in this review we discuss the “as low as reasonably achievable” (ALARA) principle, and the use of MRI as an alternative to CT. J. Magn. Reson. Imaging 2007;25:900–909. © 2007 Wiley‐Liss, Inc.

show abstract

“…Liver nodules that were enhanced during the arterial phase in a cirrhotic patient were considered HCCs. 20 The characteristic findings of HCCs such as enhancement of a pseudocapsule and internal mosaic pattern are generally better visualized on delayed phase imaging . 21 Because of the variation of signal intensity in HCC on T1-weighted images, unenhanced images are also important to determine whether the lesion is enhanced (Fig.…”

Section: Mrimentioning

confidence: 99%

The current status of imaging diagnosis of hepatocellular carcinoma

Choi

2004

Liver Transpl

View full text Add to dashboard Cite

Early detection of hepatocellular carcinoma (HCC) is important, since the most effective treatment for HCC is surgical resection or local ablation therapy when the tumor is small. Fortunately, recent advances in liver imaging techniques have facilitated the detection of small HCCs. Recent progression of noninvasive imaging technology includes various techniques of harmonic ultrasound (US) imaging with several kinds of US contrast agents, multislice helical computed tomography (CT), and rapid high-quality magnetic resonance (MR) technique with new, tissue-specific contrast agents. These techniques seem to have a strong potential to improve detection and characterization of HCC. In this review, the technique and efficacy of new imaging methods including contrast enhanced US, multislice CT, and recent MR techniques with new contrast agents for detecting and diagnosing HCC will be described.

show abstract

Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT.

Abstract: Sinusoid-phase FLASH imaging is superior to nonequilibrium-phase imaging with MR or CT for the demonstration of hypervascular malignant lesions.

Cited by 139 publications

References 0 publications

A multicenter, randomized, double‐blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

A multicenter, randomized, double‐blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI

The current status of imaging diagnosis of hepatocellular carcinoma

Contact Info

Product

Resources

About